FindTrial
Sign In

A phase I dose-escalation study testing the feasibility and the tolerance of infusion of a third party suicide gene-transduced anti-HLA-DPB1*0401 cytotoxic T cell clone in patients with HLA-DPB1*0401 positive hematologic malignancies and receiving an allotransplant from HLA-DPB1*0401 negative donors

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515504-39-00
Acronym
RC16_0157
Enrollment
6
Registered
2024-09-05
Start date
2020-02-09
Completion date
Unknown
Last updated
2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with hematological malignancies (Cf. inclusion criteria) HLA-DPB1*04:01 positive allografted with a geno- or pheno- or haplo-identical donor or cord blood HLA-DPB1*04:01 negative

Interventions

None listed

Sponsors

Centre Hospitalier Universitaire De Nantes
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026